NeoGenomics Amends 8-K Filing on Officer Changes and Compensation

Ticker: NEO · Form: 8-K/A · Filed: Feb 26, 2024 · CIK: 1077183

Sentiment: neutral

Topics: amendment, corporate-governance, executive-compensation

TL;DR

**NeoGenomics just amended an 8-K about executive changes and pay, so keep an eye on leadership stability.**

AI Summary

NEOGENOMICS INC filed an 8-K/A on February 26, 2024, amending a previous report from February 16, 2024. The filing pertains to Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers," and Item 9.01, "Financial Statements and Exhibits." The company, based in Fort Myers, Florida, operates in the testing laboratories sector.

Why It Matters

This amendment provides updated information regarding executive changes and their compensation, which can influence investor perception of leadership stability and financial health.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, indicating clarification rather than a new, unexpected event.

Key Players & Entities

FAQ

What was the earliest event reported in this 8-K/A filing?

The earliest event reported in this 8-K/A filing was on February 16, 2024.

What items are covered in this 8-K/A filing?

This 8-K/A filing covers Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers," and Item 9.01, "Financial Statements and Exhibits."

What is the business address of NEOGENOMICS INC?

The business address of NEOGENOMICS INC is 9490 NeoGenomics Way, Fort Myers, Florida 33912.

When was this 8-K/A filed?

This 8-K/A was filed on February 26, 2024.

What is the state of incorporation for NEOGENOMICS INC?

NEOGENOMICS INC is incorporated in Nevada.

Filing Stats: 695 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-02-26 16:15:17

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (a) Not applicable. (b) Not applicable. (c) Not applicable. (d) Exhibits. 10.1 Form of PSU Agreement under the NeoGenomics, Inc. 2023 Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. Date: February 26, 2024 By: /s/ Alicia C. Olivo Name: Alicia C. Olivo Title: General Counsel and Corporate Secretary

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing